Amicus Therapeutics — Q3 2021 Earnings Presentation
25 slides from Amicus Therapeutics's earnings presentation, Nov 9, 2021
Slide 1: 3Q21 Financial Results Conference Call & Webcast
3Q21 Financial Results Conference Call & Webcast November 9, 2021
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements Introduction This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from precli
Slide 3: Amicus has built a leading, fully integrated, global rare disease biotechnology company
3 Amicus has built a leading, fully integrated, global rare disease biotechnology company Gene Therapy PLATFORM Protein Engineering & Glycobiology $557M Cash as of 9/30/21 Two Clinical - Stage Gene Therapies AT - GAA Registration in Pompe Disease GLOBAL COMMERCIAL ORGANIZATION World Class BIOLOGICS
Slide 4: 2021 Key Strategic Priorities
4 2021 Key Strategic Priorities Introduction 1 2 3 4 5 Achieve double - digit Galafold growth and revenue of $300M to $315M Report data from the AT - GAA Phase 3 PROPEL study and complete BLA and MAA filings for regulatory approvals Advance clinical studies, regulatory discussions and scientific dat
Slide 5: On-Track to Complete Planned Business Combination with ARYA IV; Caritas Strategic Rationale
5 On - Track to Complete Planned Business Combination of Amicus Gene Therapy Business with ARYA IV Resulting in the Launch of Caritas Therapeutics in Late 2021/Early 2022 Caritas Strategic Rationale Introduction Enhancing the ability of both Amicus and Caritas to meet the unmet needs of patients liv
Slide 6: Galafold (migalastat) Global Launch
Galafold ® (migalastat) Global Launch… … taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 7: Galafold Snapshot (as of September 30, 2021)
7 Galafold Snapshot (as of September 30, 2021) Galafold: Precision Medicine for Fabry Disease One of the Most Successful Rare Disease Launches 348 Amenable Variants in U.S. Label 40+ Countries with Regulatory Approvals: Including U.S., EU,U.K., Japan and Other Countries Continued Expansion in 2021 $
Slide 8: Galafold Success and FY21 Revenue Guidance
8 Galafold Success and FY21 Revenue Guidance Galafold momentum remains on track to deliver within full year 2021 revenue guidance Galafold: Precision Medicine for Fabry Disease FY16 FY17 FY18 FY19 FY20 FY21 $36.9M $91.2M $260.9M FY21 Rev. Guidance $300M - $315M $182.2M $5.0M Q1 $66.4M Q2 $77.4M Q3 $
Slide 9: Galafold Long-Term Treatment Publication Key Findings
9 Galafold Long - Term Treatment Publication Key Findings 1,2 • Migalastat - treated patients had generally stable renal function for up to 8.6 years • Migalastat stabilized eGFR in ERT - naive and ERT - experienced males and females compared to historical untreated controls • Migalastat generally s
Slide 10: Outlook for 2021
10 Outlook for 2021 • Global demand remains strong with 3Q21 revenue growth rate of 18% and continued growth anticipated in 2021 and beyond • In 2021, project double - digit revenue growth with net new patient starts expected to be greater than in 2020 • Expanded EU label following the European Comm
Slide 11: Galafold Opportunity
11 $91M ~$500M Projected Revenue Galafold Opportunity Galafold: Precision Medicine for Fabry Disease With inherent Fabry market growth and our work to improve screening and diagnosis, Galafold has the potential to drive $1B+ annual revenue at peak $1B+ Opportunity Durable growth and increasing inves
Slide 12: AT-GAA: Next Potential Standard of Care for Pompe Disease
AT - GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 13: Pompe Disease Overview
13 Pompe Disease Overview Pompe disease is a severe and fatal neuromuscular disease and one of the most prevalent lysosomal disorders with very high unmet medical need AT - GAA for Pompe Disease Deficiency of GAA leading to glycogen accumulation and cellular dysfunction Age of onset ranges from infa
Slide 14: PROPEL Study Primary, Key Secondary and Biomarker Endpoint Heat Map
14 Phase 3 PROPEL Study Primary, Key Secondary and Biomarker Endpoint Heat Map AT - GAA for Pompe Disease Endpoints across motor function, pulmonary function, muscle strength, PROs and biomarkers favored AT - GAA over alglucosidase alfa Source: Presented at the 16th International Congress on Neuromu
Slide 15: AT-GAA: Highlights
15 AT - GAA: Highlights AT - GAA for Pompe Disease AT - GAA for Pompe Advances Toward Approval • U.S. FDA accepted for review the BLA and NDA for AT - GAA • MAA for AT - GAA submitted with the EMA • Granted positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the United
Slide 16: Next-Generation Gene Therapy Platform
“We have a duty to obsolete our own technologies” - Amicus Belief Statement Next - Generation Gene Therapy Platform
Slide 17: Harnessing the Power of Genetic Medicine
17 Harnessing the Power of Genetic Medicine The mission of Caritas is to transform the lives of children and adults living with rare genetic diseases through advanced protein engineering and innovative vector technologies Diversified portfolio of clinical and preclinical rare disease development pro
Slide 18: Protein Engineering Expertise & Technologies for Gene Therapy
18 Protein Engineering Expertise & Technologies for Gene Therapy Next Generation Gene Therapy Platform Differentiated gene therapy approach for greater potency and optimized cross correction through transgene engineering for stability and targeting ▪ Proprietary AAV capsid ▪ Pantropic capsid and ubi
Slide 19: Financial Summary
“We are business led and science driven” - Amicus Belief Statement Financial Summary
Slide 20: 3Q21 Select Financial Results
20 3Q21 Select Financial Results Financial Summary Sep. 30, 2021 (in thousands, except per share data) Sep. 30, 2020 Product Revenue $79,545 $67,437 Cost of Goods Sold 11,696 8,399 R&D Expense 59,333 70,419 SG&A Expense 46,107 37,850 Changes in Fair Value of Contingent Consideration 3,288 1,034 Depr
Slide 21: Financial Outlook: Key Takeaways
21 Financial Outlook: Key Takeaways • Reaffirming full - year Galafold revenue guidance of $300 million to $315 million • Non - GAAP operating expense guidance for 2021 is expected to remain flat at $410 million to $420 million • Balance sheet further strengthened with a ~$200 million private invest
Slide 22: Closing Remarks
Closing Remarks “We believe in our future to build long - term value for our stakeholders” - Amicus Belief Statement
Slide 23: Thank You
Thank You “Our passion for making a difference unites us” - Amicus Belief Statement
Slide 24: Appendix
Appendix
Slide 25: Reconciliation of Non-GAAP Financial Measures
Appendix Reconciliation Amicus Therapentics Ine. Reconciliation of Non-GAAP Financial Measures Ga thousands) “Three Months Ended September 30, 0 “Total operating expenses a reported GAAP 5 1036 $e ans ses 8066 2a 20,699 wen 3288 10M 4780 2680 1520 2336 4601 6299 165 Base Bar EST sae racy 33 7 at